Propanc Biopharma, Inc. Net Income Loss

• Propanc Biopharma, Inc. showed a decrease of -3,136.6% in Net Income Loss from 2024 to 2025.
• This data is from Propanc Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Propanc Biopharma, Inc.'s Net Income Loss has declined by 13,175.5%.
• Historical annual values: Fiscal year 2025: -$58.92 million | Fiscal year 2024: -$1.82 million | Fiscal year 2023: -$2.66 million | Fiscal year 2022: -$2.66 million | Fiscal year 2021: -$2.03 million | Fiscal year 2020: -$4.74 million | Fiscal year 2019: -$5.76 million | Fiscal year 2018: -$7.04 million | Fiscal year 2017: -$7.87 million | Fiscal year 2016: -$9.41 million | Fiscal year 2015: -$3.41 million | Fiscal year 2014: -$829.6 thousand | Fiscal year 2013: -$1.44 million | Fiscal year 2012: -$11.43 million | Fiscal year 2011: -$2.15 million | Fiscal year 2010: -$842.5 thousand | Fiscal year 2009: -$443.8 thousand.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026